A Phase II Study of MK-3475 in Patients With Thymic Carcinoma
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 13 Jul 2017
At a glance
- Drugs Pembrolizumab (Primary)
- Indications Malignant thymoma
- Focus Therapeutic Use
- 07 Jul 2017 Planned End Date changed from 1 Dec 2017 to 1 Dec 2019.
- 07 Jul 2017 Planned primary completion date changed from 1 Jun 2017 to 1 Jun 2019.
- 06 Jun 2017 Results presented at the 53rd Annual Meeting of the American Society of Clinical Oncology